Feedback

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma

Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Yang, Zhenyun;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Fu, Yizhen;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Wu, Weijie;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Hu, Zili;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Pan, Yangxun;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Wang, Juncheng;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Chen, Jinbin;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Hu, Dandan;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Zhou, Zhongguo;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Chen, Minshan;
Affiliation
State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-Sen University Cancer Center ,Guangzhou ,Guangdong ,China
Zhang, Yaojun

Background: Systemic chemotherapy (SC) remains the only first-line treatment for unresectable intrahepatic cholangiocarcinoma (iCCA). Hepatic arterial infusion chemotherapy (HAIC) has been recently proven to be effective in managing hepatocellular carcinoma (HCC). Hence, our study aims to investigate the safety and efficacy of HAIC in treating unresectable iCCA patients. Methods: We reviewed 146 patients with unresectable iCCA who had received HAIC or SC between March 2016 and March 2022 in a retrospective manner. Outcomes of patients and safety were compared between the HAIC and SC groups. Results: There were 75 and 71 patients in the HAIC and SC groups, respectively. The median OS in the HAIC and SC groups was 18.0 and 17.8 months ( p = 0.84), respectively. The median PFS in the HAIC and SC groups was 10.8 and 11.4 months ( p = 0.59), respectively. However, the HAIC group had significantly longer intrahepatic progression-free survival (IPFS) than the SC group ( p = 0.035). The median IPFS in the HAIC and SC groups was 13.7 and 11.4 months, respectively. According to the OS ( p = 0.047) and PFS ( p = 0.009), single-tumor patients in the HAIC group appeared to benefit more. In addition, the overall incidence of adverse events (AEs) was lower in the HAIC group than that in the SC group. Conclusion: Our study revealed that HAIC was a safe and effective therapeutic regimen for unresectable iCCA with better intrahepatic tumor control when compared to SC. Meanwhile, patients with single tumor were more likely to benefit from HAIC than SC.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Yang, Fu, Wu, Hu, Pan, Wang, Chen, Hu, Zhou, Chen and Zhang.

Use and reproduction: